Durie, M.G.(Brian Durie)
neuropathy patient bortezomib-induced myeloma grade bortezomib treatment cycle development intron vincristine-induced late-onset coding early-onset table non-synonymou signi ﬁcant snps late-onset bortezomib-induced myeloma plasma cells expression analysis induction factor 2–4 apoptosi pathway trial cancer study vincristine report signi system early-onset bortezomib-induced research gene expression protein number induction treatment grade 1 late-onset vincristine-induced phase baseline repair november article /oncology ﬁcant www.thelancet.com polymorphism myeloma-related factors cell cycle ppard value webappendix e ﬀect ﬂammatory sod 2 side-e ﬀect response function array dexamethasone antigen association plasma enzyme blood grade 1 bortezomib-induced gene expression arrays corthal vincristine-based induction treatment hovon -65/gmmg trial ﬁcation european hematology association dexamethasone 40 mg dorsal root ganglia proin ﬂammatory genes change hovon
1 Most Recent Publications
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Broyl, A. Corthals, S.L. Durie, M.G. Goldschmidt, H. Sonneveld, P. Jongen, J.L.M. Holt, B. van der Kuiper, R. Knegt, Y. de Duin, M. van Jarari, L. Bertsch, U. Lokhorst, H.M.